Chapter 306 - 218: Hongmen Banquet and the Drop: The "Fengmu Tiada" Entry

Chapter 306: Chapter 218: Hongmen Banquet and the Drop: The "Fengmu Tiada" Entry

Before Jin Yihong could even respond to Xu Kunlin’s offer, Lou Musaang rejected it outright.

Lou Musaang had strikingly pale skin and exuded a cool, almost sickly, aura. Though he was only thirty-six, a third of his hair had already turned silver.

His features possessed a refined beauty, which contrasted with his unhealthy complexion. Combined with his silver hair, it gave him a powerful presence.

Lou Musaang’s blunt refusal clearly angered Xu Kunlin.

He made his stance clear to Jin Yihong, Lou Musaang, and Jia Jun.

If Jin Pharmaceutical Group refused to cooperate on the project’s acquisition, the Pfizer Jin Country Research Center would immediately launch a rival project.

As a top R&D scientist, Xu Kunlin presented a proposal for a competing product designed from the ground up to rival the Yangzheng Xiujie Pill.

He added that Pfizer would invest a staggering two billion in the first phase of this project alone.

Xu Kunlin’s research talent was on par with Lou Musaang’s. With the backing of Pfizer’s mature infrastructure, massive scale, and vast resources and talent, the threat truly put immense pressure on Jia Jun.

Jin Yihong’s brow furrowed slightly.

However, as a domestic pharmaceutical company determined to be self-reliant in its research and development, the team of Jin Yihong, Lou Musaang, and Jia Jun chose to meet the challenge head-on.

Lou Musaang stated with complete confidence that by the time Pfizer managed to produce a rival product, Jin Pharmaceutical Group’s new drug would already be on the market and have established its dominance.

To this, Xu Kunlin retorted that it remained to be seen who would come out on top.

They had lost the battle for Wu Ting’s team, but they would not be defeated again—not in this competition over a rival to the Yangzheng Xiujie Pill!

The meeting, which had grown incredibly tense, finally ended on a sour note.

As for Wu Ting, he never even got a chance to speak.

[Ding! Congratulations, Host, for participating in a tense and cutthroat meeting of scientific and business minds with the nation’s top pharmaceutical R&D scientists—a true feast fraught with peril. You have obtained a trait from Professor Jia Jun: Pharmaceutical Insights for the Yangzheng Xiujie Pill (Purple). This is a traditional Chinese medicine used in oncology. It works by reducing damage to white blood cells and boosting the body’s vital energy, providing therapeutic benefits for tumors... Its greatest effects are protecting liver function, promoting hemoglobin production, and improving the patient’s quality of life... The formula is nearing completion.]

[Note: Ingredients: Huangqi, Ligustrum Fruit, ginseng, Curcuma, Reishi mushroom, Jiaogulan, fried Atractylodes, Half-branch Lotus, Hedyotis diffusa, Poria, ground beetle, chicken gizzard lining, mock strawberry, bittersweet, Artemisia capillaris, Cynanchum paniculatum...]

[Congratulations, Host! You have obtained a trait from Lou Musaang: Pharmaceutical Insights for the New Compound Medicine for Banzhe (Purple). This is a brand new, semi-finished drug for primary liver cancer. It has the potential to treat malignant tumors such as primary liver cancer, lung cancer, colorectal cancer, prostate cancer, bladder cancer, malignant lymphoma, gynecological malignancies (ovarian, endometrial, breast, choriocarcinoma, etc.), thyroid cancer, bone cancer, and nasopharyngeal carcinoma. Unfortunately, it is not yet complete.]

[Note: Ingredients: Mimosa, Acanthopanax Senticosus, Curcuma, Bear Gall Powder, ginseng, Sanling, Cornelian Cherry, licorice, Huangqi, Half-branch Lotus, Ligustrum Fruit...]

[You have obtained a trait from Xu Kunlin: Pharmaceutical Insights for the Western Medicine Sorafenib (Purple). This is a new drug for treating late-stage hepatitis B. While it has significant efficacy, it also has pronounced side effects. It is a semi-finished product with immense toxicity, rendering it unsuitable for market release...]

[Note: Specific toxic side effects include: circulatory system side effects, increased blood pressure, subungual splinter hemorrhages, cardiovascular events, thrombotic diseases, adverse skin reactions like hand-foot syndrome and facial rashes, diarrhea, and adverse hematopoietic reactions. Moreover, it has a chance of causing hepatobiliary abnormalities and increasing the risk of bleeding...]

[You have obtained a trait from Xie Bin: Business Stratagem (Purple). This encompasses Xie Bin’s business warfare techniques: a calm and seasoned mindset, cautious and methodical with every move being lethal. It includes various ruthless business tactics, subtle schemes to manipulate people, and the decisiveness for a lightning-fast, fatal strike.]

[Recommended Trait Synthesis: Pharmaceutical Insights for Yangzheng Xiujie Pill (Purple) + Pharmaceutical Insights for the New Compound Medicine for Banzhe (Purple) + Insights for Locust Tree Ear Granules (Purple) = Perfect New Drug "Fengmu Tiada" (Black). This is a new drug for primary liver cancer associated with hepatitis B, recorded in the classics of National Medicine. It combines the strengths of all three traditional Chinese medicines...]

[Missing Trait: Insights for Locust Tree Ear Granules (Purple). A traditional Chinese medicine developed by refining Locust Tree Ear Fungus...]

Wu Ting was ecstatic as he read the notification.

’I’ve just collected two top-tier traits at once. Now, all I need to do is find a scientist in the country who is researching Locust Tree Ear Fungus.’

’My new drug, Fengmu Tiada, is within reach.’

’And once I complete the R&D for this drug, my fourth stage will become truly complete! That’s an epoch-making, genuinely staggering undertaking.’

At the same time, Wu Ting was surprised to learn that Xu Kunlin had also developed a new Western drug for late-stage hepatitis B. It was a shame the drug had such immense toxic side effects.